Who Generates Higher Gross Profit? Eli Lilly and Company or Taro Pharmaceutical Industries Ltd.

Eli Lilly's Gross Profit Dominance Over Taro

__timestampEli Lilly and CompanyTaro Pharmaceutical Industries Ltd.
Wednesday, January 1, 201414683100000580006000
Thursday, January 1, 201514921500000676585000
Friday, January 1, 201615567200000778966000
Sunday, January 1, 201716801100000671251000
Monday, January 1, 201816811600000463508000
Tuesday, January 1, 201917598300000445724000
Wednesday, January 1, 202019056500000399725000
Friday, January 1, 202121005600000296656000
Saturday, January 1, 202221911600000293122000
Sunday, January 1, 202327041900000268323000
Monday, January 1, 202436624400001304979000
Loading chart...

Unleashing insights

A Tale of Two Pharmaceutical Giants: Eli Lilly vs. Taro

In the competitive world of pharmaceuticals, gross profit is a key indicator of a company's financial health and market prowess. Over the past decade, Eli Lilly and Company has consistently outperformed Taro Pharmaceutical Industries Ltd. in terms of gross profit. From 2014 to 2023, Eli Lilly's gross profit surged by approximately 84%, peaking at a staggering $27 billion in 2023. In contrast, Taro's gross profit saw a decline, dropping to around $268 million in the same year, marking a decrease of over 50% from its 2016 peak.

This stark contrast highlights Eli Lilly's robust growth trajectory and market dominance, while Taro faces challenges in maintaining its profitability. The data underscores the importance of strategic innovation and market adaptation in the pharmaceutical industry, where financial performance can vary significantly between competitors.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025